DIM-C-pPhCO2Me

Product NameDIM-C-pPhCO2Me
CAS151358-48-4
MFC25H20N2O2
MW380.44
EINECS
MOL File151358-48-4.mol

Chemical Properties

Melting point	98-100 °C
Boiling point	618.6±50.0 °C(Predicted)
Density	1.287±0.06 g/cm3(Predicted)
storage temp.	2-8°C(protect from light)
solubility	DMSO:100.5(Max Conc. mg/mL);264.16(Max Conc. mM) Ethanol:38.0(Max Conc. mg/mL);99.88(Max Conc. mM)
pka	16.34±0.30(Predicted)
form	Solid
color	Light yellow to yellow
InChI	1S/C25H20N2O2/c1-29-25(28)17-12-10-16(11-13-17)24(20-14-26-22-8-4-2-6-18(20)22)21-15-27-23-9-5-3-7-19(21)23/h2-15,24,26-27H,1H3
InChIKey	BBAOKSZCULLDIW-UHFFFAOYSA-N
SMILES	O=C(OC)C1=CC=C(C(C2=CNC3=C2C=CC=C3)C4=CNC5=CC=CC=C54)C=C1

Safety Information

WGK Germany	WGK 3
HS Code	2933998090
Storage Class	11 - Combustible Solids

Usage And Synthesis

Uses

DIM-C-pPhCO2Me is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhCO2Me induces Apoptosis. DIM-C-pPhCO2Me decreases PAX3-FOXO1A, N-Myc, Rassf4, MyoD1, Grem1, and DAPK1 proteins. DIM-C-pPhCO2Me decreases expression of TXNDC5 and IDH1, induces markers of ER stress (CHOP, ATF4 and p-PERK). DIM-C-pPhCO2Me inhibits renal cell carcinoma, breast cancer. DIM-C-pPhCO2Me can also be used in rhabdomyosarcoma research[1][2][3][4][5].

Biological Activity

DIM-C-pPhCO2Me is a NR4A1 (Nur77) antagonist th at exhibit potent anticancer activity in pancreatic, colon, breast, kidney, and rhabdomyosarcoma cells. DIM-C-pPhCO2Me decreases expression of PAX3-FOXO1A and β1-integrin proteins in Rh30 rhabdomyosarcoma and MDA-MB-231 breast cancer cells. DIM-C-pPhCO2Me inhibits migration of Rh30 and MDA-MB-231 cancer cells.', 'DIM-C-pPhCO2Me is also known as 1,1-bis(3μ-indolyl)-1-(p-carboxymethylphenyl)methane. In pancreatic and colon cancer cells, DIM-C-pPhCO2Me plays an inhibitory role on cell migration. DIM-C-pPhCO2Me prevents the action of mechanistic target of rapamycin (mTOR) and reduces the multiplication and survival of cancer cells. It stimulates reactive oxygen species (ROS) in various cancer cell lines.

in vivo

DIM-C-pPhCO2Me (2 mg/kg, single dose, intratracheally, 30 min before E. coliinfection) results in augmented phagocytic activity of AMs and reduces the mortality of mice with E. coli pneumonia^[5].

Animal Model:	Male mice with E. coli pneumonia^[5]
Dosage:	2 mg/kg, single dose
Administration:	intratracheally, 30 min before E. coli infection
Result:	Showed an obvious augmented phagocytic activity. Reduced the mortality in mice undergoing E. coli pneumonia (36.6% vs. 75%).

IC 50

Nur77/NR4A1; IDH1

References

[1] Hedrick E, et al. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma. PLoS One. 2015 Jun 2;10(6):e0128308. DOI:10.1371/journal.pone.0128308
[2] Hedrick E, et al. Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy. Endocr Relat Cancer. 2015 Oct;22(5):831-40. DOI:10.1530/ERC-15-0063
[3] Lacey A, et al. Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma. Mol Cancer Ther. 2018 Dec;17(12):2756-2766. DOI:10.1158/1535-7163.MCT-18-0118
[4] Lacey A, et al. PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1. Cancer Res. 2017 Feb 1;77(3):732-741. DOI:10.1158/0008-5472.CAN-16-1546
[5] Cui P, et al. Deficiency of the Transcription Factor NR4A1 Enhances Bacterial Clearance and Prevents Lung Injury During Escherichia Coli Pneumonia. Shock. 2019 Jun;51(6):787-794. DOI:10.1097/SHK.0000000000001184

DIM-C-pPhCO2Me Supplier

DIM-C-pPhCO2Me manufacturers

Related Product Information

Send Inquriy